|
15 Apr 2021 |
Arrowhead Announces ARO-DUX4 as First Muscle Targeted RNAi Candidate Using TRiMTM Platform
|
|
14 Apr 2021 |
Agenus Doses First Cancer Patient with iNKT Cell Therapy
|
|
14 Apr 2021 |
TriSalus Life Sciences Presents Data at American Association of Cancer Research Showing Reduced Liver Tumor Burden from Toll-Like Receptor Agonists
|
|
14 Apr 2021 |
TILT Biotherapeutics and MSD to Collaborate on Clinical Trial of Adenoviral Cancer Immunotherapeutic TILT-123 in Combination with KEYTRUDA® (pembrolizumab) for Ovarian Cancer
|
|
12 Apr 2021 |
Rubius Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial of RTX-321 for the Treatment of HPV 16-Positive Cancers
|
|
12 Apr 2021 |
Mirum Pharmaceuticals and Vivet Therapeutics Enter into Exclusive Worldwide Option and License Agreement for Vivet’s Gene Therapy Programs Targeting Progressive Familial Intrahepatic Cholestasis
|
|
12 Apr 2021 |
Taysha Gene Therapies Acquires Exclusive Worldwide Rights to Clinical-Stage AAV9 Gene Therapy Program, Now Known as TSHA-120, for the Treatment of Giant Axonal Neuropathy, a Rare and Severe Neurodegenerative Disease
|
|
12 Apr 2021 |
Seneca Therapeutics Reports Late Breaking Information on SVV-001 from the American Association for Cancer Research’s 2021 Annual Meeting
|
|
12 Apr 2021 |
Alnylam Presents Positive Late-Breaking Data from Ongoing Phase 1 Study of ALN-AGT, an Investigational RNAi Therapeutic for the Treatment of Hypertension
|
|
12 Apr 2021 |
Checkmate Pharmaceuticals Presents New Clinical Trial Translational Data with Vidutolimod at the 2021 American Association for Cancer (AACR) Annual Meeting
|
|
11 Apr 2021 |
Phio Pharmaceuticals Presents Positive In Vivo Data Showing Strong Tumor Control for the Intratumoral Delivery of INTASYL™ RNAi Targeting PD-1
|
|
11 Apr 2021 |
Synlogic Presents Data from SYNB1891 Phase 1 Trial at American Association for Cancer Research (AACR) Annual Meeting
|
|
11 Apr 2021 |
SQZ Biotech Presents Preclinical Data on its mRNA-based enhanced APCs and the Potential of the SQZ APC Platform in KRAS Driven Tumors
|
|
11 Apr 2021 |
OncoMyx Presents at AACR First Data Showing Multi-Armed Myxoma Virotherapy Can Modulate Anti-Tumor Immune Response
|
|
09 Apr 2021 |
IN8bio Demonstrates In Vitro Activity of DeltEx DRI CAR-T Cells Against Glioblastoma Multiforme at AACR
|
|
09 Apr 2021 |
Transgene Presents Initial Phase I Data of TG6002, Highlighting the Potential of the Intravenous Administration of Its Oncolytic Viruses
|
|
07 Apr 2021 |
Arcellx Announces FDA Clearance of IND Application for ACLX-001, a Controllable Cell Therapy Utilizing the Company’s ARC-SparX Platform, for the Treatment of Multiple Myeloma
|
|
05 Apr 2021 |
Ionis initiates Phase 3 trial of novel antisense medicine to treat leading cause of juvenile-onset ALS
|
|
02 Apr 2021 |
Passage Bio Announces First Patient Dosed in Imagine-1 Study of PBGM01 Gene Therapy for Infantile GM1 Gangliosidosis
|
|
02 Apr 2021 |
Kite Submits Supplemental Biologics License Application to U.S. Food and Drug Administration for Tecartus in Adult Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia
|
|
31 Mar 2021 |
Istari Oncology Announces First Patient Dosed in the LUMINOS-102 Phase 2 Clinical Trial of PVSRIPO With and Without Immune Checkpoint Blockade in Advanced PD-1/L1 Refractory Melanoma
|
|
30 Mar 2021 |
Stoke Therapeutics Announces MHRA Authorization to Initiate Phase 1/2a Clinical Trial of STK-001 for Dravet Syndrome in the United Kingdom
|
|
29 Mar 2021 |
Ionis reports positive topline Phase 2 study results of its novel antisense treatment for hereditary angioedema
|
|
27 Mar 2021 |
U.S. Food and Drug Administration Approves Bristol Myers Squibb’s and bluebird bio’s Abecma (idecabtagene vicleucel), the First Anti-BCMA CAR T Cell Therapy for Relapsed or Refractory Multiple Myeloma
|
|
25 Mar 2021 |
Synlogic Announces SYNB8802 Will Advance to Phase 1B Proof of Concept Study After Proof of Mechanism Demonstrated in Dietary Hyperoxaluria
|
